InFocus: Life Sciences & Healthcare e-newsletter - February 2006

In this issue we discuss:

• Interpretation issues arising from the implementation of the new bolar exemption
• The debate on parallel trade in dominant pharmaceuticals; where are we after the ECJ’s rejection of Syfait v Glaxosmithkline?
• The ambit of Article 82 after the AstraZeneca case
• Controversial ID cards and a recent report on biometrics that adds fuel to the flaming fire
• What action can a trade mark proprietor take against original goods from outside the EU imported and temporarily stored in a custom’s warehouse?
• New guidelines from the EMEA on Biosimilars
• The Commission's draft Regulation on “advanced therapies”
• Patent Agent legal advice privilege
• The perils of deleting or not deleting documents from your computer

About Taylor Wessing's Life Sciences & Healthcare Group

Taylor Wessing's market-leading Life Sciences & Healthcare Group provides a top quality, multi-disciplinary service.  The Group combines Taylor Wessing’s top-rated intellectual property and venture capital lawyers with specialists from our highly acclaimed international corporate, corporate finance, employment and real estate practices.  We advise life sciences and healthcare businesses, those who fund them and those who work for them.

For more information about Taylor Wessing's Life Sciences & Healthcare Group, please click here.

For any legal enquiries, please contact Daniel Pavin or your usual contact at Taylor Wessing.  For any marketing and business development enquiries, please contact Sharon Philbey.